Biotech
$ECTE Symphony Glucose Monitoring System is Key Valuation Catalyst
Written by Mike Havrilla–Echo Therapeutics (NASDAQ:ECTE) is a medical device company focused on the development of new products based upon its advanced skin permeation technology platform.
Continue reading...New Phase 3 Catalyst Trade for Mike with Strong Balance Sheet
9 February 2012 – 12:16 am PST
$EXAS Key Data for Colon Cancer Screening Test Expected Around 3Q12
7 February 2012 – 12:16 am PST
Written by Mike Havrilla–EXACT Sciences (NASDAQ:EXAS) is a molecular diagnostics company focused on the late-stage development of a new non-invasive, genetic (DNA) based screening test (Cologuard) designed to improve the rate of early detection of colorectal cancer (CRC).
Continue reading...$ANAC Expects to Report Initial Phase 3 Data in Late 2012
2 February 2012 – 12:16 am PST
Written by Mike Havrilla–Anacor Pharma (NASDAQ:ANAC) is focused on the mid to late stage clinical development of anti-fungal, antibiotic and anti-inflammatory therapeutics. Below is a summary of the Company’s pipeline.
Continue reading...
9 February 2012 – 12:16 am PST
View Comments